Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02), Fidelity Earnings reports. The company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%.
Aurinia Pharmaceuticals stock opened at $5.22 on Friday. Aurinia Pharmaceuticals has a 1 year low of $3.52 and a 1 year high of $7.85. The company has a market cap of $504.42 million, a P/E ratio of -6.87 and a beta of 1.07. The firm’s 50-day moving average is $4.95 and its 200-day moving average is $5.89.
Several research analysts have weighed in on AUPH shares. ValuEngine lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 10th. Royal Bank of Canada reissued a “buy” rating and set a $11.00 price objective on shares of Aurinia Pharmaceuticals in a report on Thursday, August 8th. Oppenheimer began coverage on shares of Aurinia Pharmaceuticals in a research report on Tuesday, September 10th. They issued an “outperform” rating and a $14.00 price target on the stock. HC Wainwright set a $25.00 price target on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 1st. Finally, Citigroup began coverage on shares of Aurinia Pharmaceuticals in a research report on Monday, September 9th. They issued an “outperform” rating and a $14.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Aurinia Pharmaceuticals has an average rating of “Buy” and a consensus target price of $15.18.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Article: What is the LIBOR?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.